DiaMedica Therapeutics (DMAC) Net Income towards Common Stockholders (2018 - 2026)
DiaMedica Therapeutics (DMAC) reported Net Income towards Common Stockholders of -$10.0 million for Q1 2026, down 30.3% on a YoY basis from -$14.4 million in Q1 2025, and down 10.1% quarter-over-quarter from -$9.1 million in Q4 2025.
DiaMedica Therapeutics (DMAC) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics has reported Net Income towards Common Stockholders for 9 years, with the latest figure at -$10.0 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 30.3% year-over-year to -$10.0 million; the trailing twelve-month figure through Mar 2026 stood at -$35.5 million (down 31.23% YoY), and the FY2025 full-year result was -$33.1 million, down 35.39% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$10.0 million, down from -$9.1 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$3.1 million in Q3 2022, with the low at -$10.0 million in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged -$5.9 million across 5 years, with a median of -$5.2 million in 2023.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders advanced 11.33% — and 2024, when it tumbled 53.81%.
- DiaMedica Therapeutics' Net Income towards Common Stockholders stood at -$3.8 million in 2022, then tumbled by 37.59% to -$5.2 million in 2023, then tumbled by 53.81% to -$7.9 million in 2024, then retreated by 14.9% to -$9.1 million in 2025, then retreated by 10.1% to -$10.0 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$10.0 million (Q1 2026), -$9.1 million (Q4 2025), and -$8.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | DiaMedica Therapeutics | 285.11 Mn | 233.77 Mn | - | -10.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.04 Mn |
| Dec 31, 2025 | -9.12 Mn |
| Sep 30, 2025 | -8.62 Mn |
| Jun 30, 2025 | -7.70 Mn |
| Mar 31, 2025 | -7.71 Mn |
| Dec 31, 2024 | -7.94 Mn |
| Sep 30, 2024 | -6.27 Mn |
| Jun 30, 2024 | -5.12 Mn |
| Mar 31, 2024 | -5.15 Mn |
| Dec 31, 2023 | -5.16 Mn |
| Sep 30, 2023 | -4.47 Mn |
| Jun 30, 2023 | -4.48 Mn |
| Mar 31, 2023 | -5.27 Mn |
| Dec 31, 2022 | -3.75 Mn |
| Sep 30, 2022 | -3.06 Mn |
| Jun 30, 2022 | -3.36 Mn |
| Mar 31, 2022 | -3.51 Mn |
| Dec 31, 2021 | -3.25 Mn |
| Sep 30, 2021 | -3.45 Mn |
| Jun 30, 2021 | -3.27 Mn |